Status:
COMPLETED
DNA Vaccine for Ragweed Allergic Adults
Lead Sponsor:
Johns Hopkins University
Conditions:
Seasonal Allergic Rhinitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Various chemical modifications of allergens have been attempted to enhance efficacy, improve safety, and foster compliance with IT. These approaches have been unsuccessful - in that the allergenicity ...
Detailed Description
Evaluation of efficacy and safety of allergen-CpG oligonucleotide immunostimulatory conjugate in treatment of ragweed-induced seasonal allergic rhinitis. Study incorporates clinical outcomes (symptom ...
Eligibility Criteria
Inclusion
- Adult men and women 18 to 60 years of age;
- Who provide informed consent;
- Have a history of fall, seasonal, allergic rhinitis consistent with ragweed allergy;
- Exhibit a positive skin test to licensed , standardized, ragweed extract and a positive acute response to ragweed nasal challenge;
- Are in general good health; and are available for the duration of the study.
Exclusion
- Individuals with medical conditions or taking medications that might interfere with interpretation of the study results will be excluded.
- Those with a history of severe symptoms of allergic rhinitis during the spring and summer grass pollen season will be excluded.
Key Trial Info
Start Date :
May 18 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 21 2001
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00346086
Start Date
May 18 2001
End Date
August 21 2001
Last Update
December 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21224